

# Prevention, diagnosis and management of delirium in the DCCM[Title]

Unique Identifier	[Category]
Document Type	Clinical Guideline
Risk of non-compliance	may result in significant harm to the patient/DHB
Function	Clinical Practice, Patient Care
User Group(s)	Auckland DHB only
<ul> <li>Organisation(s)</li> </ul>	Auckland District Health Board
<ul> <li>Directorate(s)</li> </ul>	
<ul> <li>Department(s)</li> </ul>	Department of Critical Care Medicine
• Used for which patients?	
• Used by which staff?	All medical and nursing staff providing care for patients in the DCCM
Excluded	Patients with medical requirements for deep sedation (RASS less than -3, e.g. for severe respiratory failure, management of raised intracranial pressure), patients at risk of or experiencing acute alcohol or drug withdrawal, patients with acute psychosis.
Keywords	
Author	Kylie Julian (ADHB)
Authorisation	
• Owner	<designation></designation>
Delegate / Issuer	<designation></designation>
Edited by	
First issued	Click here to enter a date.
This version issued	[Publish Date] - Choose an item.
Review frequency	3 yearly
Associated documents:	Sedation SOP, DCCM Restraint Minimisation Policy, Lighting in the DCCM.

# Contents

1.	Purpose of policy OR guideline (delete one) Error! Bookmark not defined.
2.	Policy statements OR Guideline management principles and goals (delete one)Error!
Boo	kmark not defined.
3.	Definitions Error! Bookmark not defined.
4.	Supporting evidence
5.	Legislation7
6.	Associated document9
7.	Disclaimer9
8.	Corrections and amendments10



# **Purpose of Guideline**

To guide the prevention, recognition and management of delirium in patients cared for in the Department of Critical Care Medicine (DCCM)

### **Guideline Management Principles and Goals**

### Delirium

Delirium is characterised by acute onset of altered consciousness and cognition. Delirious patients commonly have impaired attention and disorganised thinking. Delirium typically has a fluctuating course. Delirium is a common complication of critical illness. It is present in over half of mechanically ventilated patients (Brummel et. al 2013).

Delirium presents in two forms; hypoactive delirium characterised by withdrawal and inattention, and agitated delirium characterised by anxiety and agitation. Three quarters of patients with delirium present with the hypoactive form (Ely et. al. 2001).

# Significance of Delirium

Adverse outcomes are associated with delirium during critical illness including higher mortality, longer ICU length of stay and longer hospital length of stay (Pisani et. al. 2009, Thomason et. al. 2005). Delirium was associated with a three-fold increase in risk of death at 6 months in ventilated patients with critical illness after controlling for comorbidities and severity of illness (Ely et. al. 2004). Duration of delirium has been associated with worse long term cognitive outcomes in survivors of critical illness (Girard et. al. 2010).

# **Risk factors for Delirium**

Risk factors predisposing to delirium include advanced age, multiple comorbidities, cognitive impairment and sensory impairment. Precipitating risk factors include pain, sleep disruption, illness severity and prescription of benzodiazepines (Devlin et. al 2018, Marcantonio 2017, Pisani et. al. 2007, Seymour et. al. 2012, Zaal et. al. 2015). In general, when more predisposing risk factors are present, fewer precipitating risk factors are required for delirium to occur (Inouye et. al 1993).

Hospitalised elderly medical patients are at high risk of delirium when they have three or more risk factors (Inouye et. al 1993). Patients critically unwell in intensive care will commonly have many more risk factors (Ely et. al 2001).

# Screening for delirium


Less than a third of delirium is recognised in hospitalised older adults (Marcantonio 2017). Without the use of a structured diagnostic tool delirium is often undiagnosed in the critically unwell (Reade et. al 2014).

Delirium should be assessed for every shift by nursing staff, or more frequently if there is suspicion of change, using the Confusion Assessment Method for the ICU (CAM-ICU). This is a validated screening tool for delirium in the critically unwell, and can be used on all adult intensive care patients with a Richmond Agitation and Sedation Scale (RASS) of greater than -3/moderate



sedation (See appendix for details of the RASS). The CAM-ICU is the most widely used and specific of the screening tools for delirium in ICU, and has excellent reliability (Ely et. al. 2001, Sherpa et. al 2012).

The CAM-ICU establishes the presence of delirium based on the presence or absence of four factors related to attentiveness and disorganised thinking as described in the flow sheet below (Ely et. al. 2001).



Copyright © 2002, E. Wesley Ely, MD, MPH and Vanderbilt University, all rights reserved



Where clinically indicated, sedation will be titrated to the RASS. For many patients without raised intracranial pressure or high ventilator requirements, the target RASS will be 0 to -1. RASS should be assessed hourly. When deeper sedation is targeted (RASS less than -3) CAM-ICU screening is not appropriate.

The CAM-ICU should be assessed prior to the morning and evening ward rounds so that the results can be noted by the team. The CAM-ICU score will be documented on the DCCM 24 hour chart, in the comments section. The CAM-ICU assessment tool will be kept in the bedside resource folder. In patients with English as a second language a visual CAM-ICU is available.

# Screening for delirium in patients with brain injury

Fluctuation in attention and cognition are expected following brain injury such as stroke, aneurysmal sub-arachnoid haemorrhage and trauma. The CAM-ICU has been validated in patients with stroke (Mitasova et. al 2012). The CAM-ICU must be interpreted mindful of the expected clinical course and severity of cerebral insult in patients with brain injury.

#### Prevention

The patients' physical environment plays a part in preventing delirium, though evidence for any one intervention is generally poor (Devlin et. al. 2018, Herling et. al.2018).

Natural sleep patterns should be promoted. Day-night cycle should be maintained as much as possible, with day time activity and exposure to natural sunlight and quiet low-light environments at night when able.

Visual cues in the bed space to orient the patient to time and place.

Patients should have access to hearing and vision aids.

Sedation should be minimised, titrated to a goal of patients being safe, lucid and able to participate in their care.

There is no role for prophylactic pharmacotherapy in the prevention of delirium (Devlin et. al 2018).

Benzodiazepines should only be prescribed when indicated to manage raised intracranial pressure, seizures, prevent awareness and prevent or manage withdrawal states.

#### Management of delirium

# Assessment of patients with new delirium

Any patient with new delirium should be assessed to determine if new pathology has contributed to their delirium. The aide memoire Stop and Think is useful:

Stop

- Do any medications need to be stopped or reduced, especially sedatives.
- Assess for and treat pain if present

#### Think



• Toxic Situations

- New organ failure or dysfunction, drug side effect or interaction.

- Hypoxaemia.
- Infection, immobilisation.
- Non-pharmacologic interventions
  - - Noise control, natural sleep patterns, hearing aids etc.
- K or other electrolyte problems.

Other diagnoses should be considered, including exacerbation of underlying dementia, depression, acute presentation of other psychiatric disorders and withdrawal states.

# Non-pharmacologic management of patients with delirium

The measures described above in the prevention section are also utilised in the management of the delirious patient. Reorientation and reassurance should occur as often as necessary. Family involvement in care is often helpful.

# Pharmacologic management of patients with delirium

The presence of delirium does not mandate the prescription of an antipsychotic. The evidence for pharmacotherapy for delirium is generally poor. Neither typical nor atypical antipsychotics are associated with shorter duration of delirium (Burry et. al 2018). The focus should be on non-pharmacologic management. Drug therapy is reserved for patients who are unsafe or who have distressing symptoms (Devlin et. al. 2018). Factors that influence the drug therapy chosen include the degree of agitation, the co-prescription of other QT prolonging medications and the QTc on ECG. Therapy should cease when symptoms of delirium resolve, defined by the presence of three consecutive CAM-ICU assessments negative for delirium, each at least 12 hours apart.

# First line rescue therapy for acute agitation

# Haloperidol

Typical antipsychotic, most QT prolonging of therapies for delirium Does not increase delirium free days Dose 0.5-2.5mg IV/PO/SC/IM PRN Usual maximum dose 10mg/day

# Second line background therapy for on-going agitation

# Quetiapine

Atypical antipsychotic. More sedating than risperidone. Moderate QT prolongation. Dose 12.5-50 mg PO/NG Q24h-Q12h Usual maximum dose 100mg/24h

# Risperidone

Atypical antipsychotic. Mild QT prolongation. Dose 0.5-1 mg PO/NG Q12h Usual maximum dose 4 mg/day



# Olanzapine

Atypical antipsychotic. Available in orodispersible wafer, bioequivalent to PO tablet. Response is poorer than other antipsychotics in patients >75 years old. Mild QT prolongation Dose 5-10 mg PO Q24h up to 20 mg/day (Start at 2.5mg PO Q24h in the elderly)

# Dexmedetomidine

Alpha-2 adrenergic agonist. May have a role as treatment for agitation which prevents extubation (Reade et.al. 2016)

Dose 0.3-1.5 mcg/kg/hr IV infusion. Usual starting dose 0.5 mcg/kg/hr, increase in 0.1 mcg/kg/hr increments

# Benzodiazepines

Indicated for agitation associated with withdrawal states. Not indicated in the management of delirium other than in exceptional circumstances where agitation poses a risk to the patient or staff.

# Supporting evidence: References

Brummel NE, Vasilevskis EE et. al. Implementing delirium screening in the Intensive Care Unit: Secrets to success. Crit Care Med 2013;41(9):2196-2208

Burry L, Hutton B et. al. Pharmacological interventions for the treatment of delirium in critically ill adults. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD011749

Devlin JW, Skrobik Y et. al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018;46:e825-e873

Ely EW, Shintani A et. al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753-1762

Ely EW, Gautam S et. al. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med 2001;27:1891-1900

Ely EW, Margolin R et. al. Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001;29:1370-1379



Ely EW, Inouye SK et. al. Delirium in mechanically ventilated patients: Validity and reliability of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). JAMA 2001;286(21):2703-2710

Girard TD, Jackson JC et. al. Delirium as a predictor of long term cognitive impairment in survivors of critical illness. Crit Care Med 2010;38(7):1513-1520

Herling SF, Greve IE et. al. Interventions for preventing intensive care delirium in adults. Cochrane Database of Systematic Reviews 2018, Issue 11. Art. No.: CD009783

Marcantonio ER. Delirium in Hospitalised Older Adults. N Engl J Med 2017;377:1456-66

Mitasova A, Kostalova M et. al. Poststroke delirium incidence and outcomes: Validation of the Confusion Assessment Method for the Intensive Care Unit. Crit Care Med 2012;40:484-90

Pisani MA, Kong SYJ et. al. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med 2009;180:1092-1097

Pisani MA, Murphy TE et. al. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med 2007;167(15):1629-34

Reade MC, Eastwood GM et. al. Effect of dexmedetomidine added to standard care on ventilatorfree time in patients with agitated delirium: A remadomsed clinical trial. JAMA 2016;315:1460-68

Reade MC, Finfer S. Sedation and Delerium in the Intensive Care Unit. N Engl J Med 2014;370:444-54

Seymour CW, Pandharipande ME et. al. Diurnal sedative changes during intensive care: impact on liberation from mechanical ventilation and delirium. Crit Care Med 2012;40(10):2788-96

Sherpa Neto A, Nassar AP et. al. Delirium screening in critically ill patients: A systematic review and meta-analysis. Crit Care Med 2012;40:1946-1951

Thomason JWW, Shintani A et. al. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. Critical Care 2005;9:R375-R381

Zaal IJ, Devlin JW et. al. A systematic review of risk factors for delirium in the ICU. Crit Care Med 2015;43:40-47

# Supporting Evidence: Bibliography

Ely EW, Truman B et. al. Monitoring sedation status over time in ICU patients: Reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003;289(22):2983-2991

Inouye SK, Viscoli CM et. al. A predictive model for delirium in hospitalised elderly medical patients based on admission characteristic. Ann Intern Med 1993;119:474-481




Lin SM, Huang CD et. Al. Risk factors for the development of early-onset delirium and the subsequent clinical outcome in mechanically ventilated patients. J Crit Care 2008;23:372-379

Zayed Y, Barbarawi M et. al. Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomised controlled trials. J Crit Care 2019;50:280-286



# Appendix 1: The Richmond Agitation and Sedation Scale (RASS)



Ely EW, Truman B, Shintani A, Thomason JWW, Wheeler AP, Gordon S et al. Monitoring sedation status over time in ICU patients: the reliability and validity of the Richmond Agitation Sedation Scale (RASS). JAMA 2003; 289:2983-2991.

Legislation

# **Associated documents**

# Disclaimer

No guideline can cover all variations required for specific circumstances. It is the responsibility of the health care practitioners using this Auckland DHB guideline to adapt it for safe use within their own institution, recognise the need for specialist help, and call for it without delay, when an individual patient falls outside of the boundaries of this guideline.



# **Corrections and amendments**

The next scheduled review of this document is as per the document classification table (page 1). However, if the reader notices any errors or believes that the document should be reviewed **before** the scheduled date, they should contact the owner or <u>Document Control</u> without delay.